Interleukin-1β induced activation of nuclear factor-κb can be inhibited by novel pharmacological agents in osteoarthritis

Rheumatology

Volumn 46, Issue 5, 2007, Pages 752-758

  Lauder, S N ^a   Carty, S M ^a   Carpenter, C E ^a   Hill, R J ^b   Talamas, F ^b   Bondeson, J ^a   Brennan, P ^a   Williams, A S ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b Roche   (United States)

Author keywords

Cytokines; Matrix Metalloproteinases; NF B; Osteoarthritis; Therapeutics

Indexed keywords

I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA ANTIBODY; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; NEUTRALIZING ANTIBODY; PROTEIN KINASE INHIBITOR; RO 100; RO 919; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MACROPHAGE; OSTEOARTHRITIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; STATISTICAL SIGNIFICANCE; SYNOVIOCYTE; SYNOVIUM; TRANSCRIPTION INITIATION; BIOSYNTHESIS; CELL CULTURE; COCULTURE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GEL MOBILITY SHIFT ASSAY; METABOLISM; METHODOLOGY; PATHOLOGY; SIGNAL TRANSDUCTION;

ANTIRHEUMATIC AGENTS; CELLS, CULTURED; COCULTURE TECHNIQUES; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-1BETA; INTERLEUKIN-6; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 3; NF-KAPPA B; OSTEOARTHRITIS; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; SYNOVIAL MEMBRANE;

EID: 34347219808     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel419     Document Type: Article

References (41)

1. Birchfield PC. Osteoarthritis Overview. Gedatr Nurs 2001;22:124-31.
2. Ehrlich GE. Osteoarthritis beginning with inflammation. JAMA 1975;232:691-3.
3. Smith MD, Triantafillou S, Parker A, Youssef PP, Coleman S. Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheum 1997;24:365-71.
4. Benito MJ, Veale DJ, Fitzgerald O, van den Berg WB, Breshinan B. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis 2005;65:1263-7.
5. Loeuille D, Chary-Valckenaere I, Champigneulle J et al. Macroscopic and microscopic features of synovial membrane inflammation in the osteoarthritic knee. Arthritis Rheum 2005;52:3492-501.
6. Kristofferson H, Torp-Pedersen S, Terslev L et al. Indications of inflammation visualized by unltrasound in osteoarthritis of the knee. Acta Radiolog 2006;47:281-6.
7. Huser CAM, Davies EM. Validation of an in vitro single-impact load model of the initiation of osteroarthritis-like changes in articular cartilage. J Orthopaed Res 2006;24:725-32.
8. Wilson W, van Burken C, van Donkelaar C, Buma P, van Rietbergen B, Huiskes R. Causes of mechanically induced collagen damage in articular cartilage. J Orthopaed Res 2006;24:220-8.
9. Fujisawa T, Hattori T, Takahashi K, Kuboki T, Yamashita A, Takigawa M. Cyclic mechanical stress induces extracellular matrix degradation in cultured chondrocytes via gene expression of matrix metalloproteinases and interleukin-1. J Biochem (Toyko) 1999;125:966-75.
10. Martel-Pelletier J. Pathophysioloy of Osteoarthritis. Osteoarthr Cartilage 2004;12:S31-3.
11. Martel-Pelletier J, Alaaedine N, Pelletier JP. Cytokines and their role in the pathophysiology of osteoarthritis. Front Biosci 1999;4:d694-703.
12. Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloprotainases: Role in arthritis. Front Biosci 2006;11;529-43.
13. Aigner T, Sachse A, Gebhard PM, Roach HI. Osteoarthritis: Pathobiology - targets and ways for therapeutic intervention. Adv Drug Deliver Rev 2006;58:1-22.
14. Bau B, Gebhard PM, Haag J, Knorr T, Bartnik E, Aigner T. Relative messenger RNA expression profiling of collagenases and aggrecanases in human articular chondrocytes in vivo and in vitro. Anthritis Rheum 2002;46:2648-57.
15. Kevorkian L, Young DA, Darrah C et al. Expression profiling of metalloprotainases and their inhibitors in cartilage. Arthritis Rheum 2004;50:131-41.
16. Lin PM, Chan CTC, Torzilli PA. Increased stromeolysin-1 (MMP-3), proteoglycan degradation (3B3- and 7D4) and collagen damage in cyclically load-injured cartilage. Osteoarthr Cartilage 2004;12:485-96.
17. van Meurs J, van Lent P, Holthuysen A et al. Active matrix metalloprotainases are present in cartilage during immune complex-mediated arthritis: A pivotal role for stromeolysin-1 in cartilage destruction. J Immunol 1999;163:5633-9.
18. Unemori EN, Bair MJ, Bauer EA, Amento EP. Stromeolysin expression regulates collagenase activation in human fibroblasts. J Biol Chem 1991;266:23477-82.
19. Dreier R, Gressel S, Fuchs S, Schaumburger J, Bruckner P. Pro-MMP-9 is a specific macrophage product and is activated by osteoarthritic chondrocytes Via MMP-3 or MT1-MMP/MMP-13 cascade. Exp Cell Res 2004;297:303-12.
20. Bender S, Haubeck HD, Van do Leur E et al. Interleukin-1β induces synthesis and secretion of interleukin-6 in human chondrocytes. FEBS 1990;263:321-4.
21. Pelletier JP, McCollum R, Coultier JM, Martel-Pelletier J. Synthesis of metalloproteases and interleukin-6 (IL-6) in human osteoarthritic synovial membrane is an IL-1 mediated process. J Rheumatol 1995;22:S110-4.
22. Flannery CR, Little CB, Hughes CE, Curtis CL, Caterson B, Jones SA. IL-6 and its soluble receptor augment aggrecanase-mediated proteoglycan catabolism in articular cartilage. Matrix Biol 2000;19:549-53.
23. Hayden MS, Ghosh S. Signaling to NFκB. Genes Dev 20D4;18:2195-224.
24. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M. A cytokine responsive IκB kinase that activates the transcription factor NFκB. Nature 1997;388:548-54.
25. Baldwin AS. The NFκB and IκB proteins; new discoveries and insights. Annl Rev Immunol 1996;14:649-81.
26. Amos N, Lauder S, Evans A, Feldmann M, Bondeson J. Adenoviral gene transfer into osteoarthritis synovial calls using the endogenous inhibitor IκBα reveals that most, but not all, inflammatory and destructive mediators are NFκB dependent. Rheumatology 2006;45:1201-9.
27. Liacini A, Sylvester J, Qing Li W, Zafarullah M. Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-κB) transcription factors downregulates matrix metalloproteinase gene expression in articular chondrocytes. Matrix Biol 2002;21:251-42.
28. Fan Z, Yang H, Bau B, Soder S, Aigner T. Role of mitogen-activated protein kinases and NFκB on IL-1β induced effects of collagen type II, MMP-1 and 13 mRNA expression in normal human articular chondrocytes. Rheumatol Int 2006;26:900-03.
29. Mengshol JA, Vincenti MP, Coon CI, Barchowsky A, Brinckerhoff CE. Interleukin-1 induction of collagenase-3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-JUN N-terminal kinase and nuclear factor κB. Arthritis Rheum 2000;43;801-11.
30. Dignam JD, Lebovitz RM, Roeder AG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983;11:1475-89.
31. Haywood L, McWilliams DF, Pearson CI et al. Inflammation and angiogenesis in Osteoarthritis. Arthritis Rheum 2003;48:2173-7.
32. Kurz B, Lemke AK, Fay J, Pule T, Grodzinsky AJ, Schunke M. Pathomechanisms of cartilage destruction by mechanical injury. Ann Anat 2005;187:473-85.
33. Smith GN Jr. The role of collagenolytic matrix metalloprotainases in the loss of articular cartilage destruction. Front Biosci 2006;11:3081-95.
34. Wakamatsu K, Nanki T, Miyasaka N, Umezawa K, Kubota T. Effect of a small molecule inhibitor of nuclear factor-κB nuclear translocation in a murine model of arthritis and cultured human synovial calls. Arthritis Res Ther 2005;7:R1348-59.
35. Wilczynska KM, Gopalan S, Bugno M et al. A novel mechanism of tissue inhibitor of metalloproteinases-1 activation by interleukin-1 in primary human astrocytes. J Biol Chem 2006;281:34955-64.
36. Zhang YP, Yao XX, Zhao X. Interleukin-1 beta up-regulatas tissue inhibitor of matrix metalloproteinases-1 mRNA and phosphorylation of c-jun N-terminal kinase and p38 in hepatic stellate cells. World J Gastroenter 2006;12:1392-6.
37. Brennan FM, Chentry D, Jackson AM, Maini RN, Feldmann M. Cytokine production in culture by cells isolated from the synovial membrane. J Autoimmun 1989;2:177-86.
38. Kobayashi M, Squires GR, Mousa A et al. Role of interleukin-1 and tumour necrosis factor α in matrtx degradation of human osteoarthritic cartilage. Arthritis Rheum 2005;52:128-35.
39. Chevalier X, Giraudeau B, Conrozier T, Marliere J, Kiefer P, Goupille P. Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: A multicenter study. J Rheumatol 2005;32:1317-23.
40. Klareskog L, van der Heijde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methtrexate compared with each treatment alone in patients with rheumatoid arthritis: Double blind randomised controlled trial. Lancet 2004;363:675-81.
41. Bathon JM, Martin RW, Fleischmann RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. New Engl J Med 2000;343:1586-93.